Skip to main content
Loading

Policy Outlook: IRA’s Ripple Effects on Private Companies and Investment

October 16, 2024
Venetian Room
With the first pricing negotiation results of the Inflation Reduction Act now public, analysts will be diagnosing trends for commercial companies and the implications for their pipelines. Those pipeline effects will alter how large biopharma pursue M&A and collaborate with pre-commercial biotechs particularly regarding their small-molecule or biologic asset status, which will thereby adjust the risk profile for the venture community. Join this session to discuss how best to accommodate these trends in your own strategic planning.
Moderator
Crystal Kuntz, Senior Vice President, Health Policy & Research - Biotechnology Innovation Organization (BIO)
Speakers
Raghav Aggarwal, Vice President - BGR Group
Jim Meyers, Senior Advisor - Boston Consulting Group
Steven Potts - PhD, CEO - SLAM BioTherapeutics

DOUBLE HELIX SPONSOR

HELIX SPONSOR

PREMIER SPONSOR

CONFERENCE SPONSORS